Werewolf Therapeutics (NASDAQ:HOWL) Rating Reiterated by HC Wainwright

Werewolf Therapeutics (NASDAQ:HOWL)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $15.00 price objective on the stock.

HOWL has been the topic of a number of other reports. JMP Securities reissued a “market outperform” rating and issued a $12.00 price target on shares of Werewolf Therapeutics in a report on Wednesday, June 26th. Wedbush reissued an “outperform” rating and issued a $9.00 target price on shares of Werewolf Therapeutics in a report on Monday, June 3rd.

Werewolf Therapeutics Stock Down 3.7 %

NASDAQ HOWL opened at $2.35 on Tuesday. The stock’s 50-day moving average price is $4.43 and its 200-day moving average price is $5.12. The company has a market capitalization of $102.13 million, a P/E ratio of -2.16 and a beta of 0.47. The company has a quick ratio of 6.71, a current ratio of 6.71 and a debt-to-equity ratio of 0.24. Werewolf Therapeutics has a 52 week low of $1.57 and a 52 week high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Friday, May 3rd. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). The firm had revenue of $0.74 million during the quarter, compared to analysts’ expectations of $5.00 million. Werewolf Therapeutics had a negative return on equity of 36.15% and a negative net margin of 256.33%. On average, equities research analysts predict that Werewolf Therapeutics will post -1.52 earnings per share for the current year.

Institutional Trading of Werewolf Therapeutics

A number of large investors have recently added to or reduced their stakes in HOWL. Financial Perspectives Inc raised its position in Werewolf Therapeutics by 80.0% during the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock valued at $26,000 after purchasing an additional 3,000 shares during the period. Certuity LLC purchased a new stake in Werewolf Therapeutics during the 4th quarter valued at $39,000. Lighthouse Investment Partners LLC bought a new stake in Werewolf Therapeutics in the fourth quarter worth $87,000. PFM Health Sciences LP increased its position in Werewolf Therapeutics by 35.6% during the fourth quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock valued at $13,387,000 after acquiring an additional 909,895 shares during the last quarter. Finally, Denali Advisors LLC bought a new position in Werewolf Therapeutics during the first quarter valued at $172,000. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.